Background The comparative performance of existing models for prediction of type 2 diabetes across populations has not been investigated. We validated existing non-laboratory-based models and assessed variability in predictive performance in European populations.
Introduction
The number of individuals with type 2 diabetes is high and increasing rapidly: 366 million people worldwide were estimated to have type 2 diabetes in 2011, and prevalence is expected to rise by 51% by 2030. 1 Diabetes is associated with increased morbidity and mortality, and accounts for a substantial proportion of use of health-care resources worldwide. 1 Several studies have convincingly shown that early interventions can prevent or postpone type 2 diabetes. 2, 3 The cost of these interventions and their constraints for individuals are arguments against their provision, particularly for people at low risk of diabetes. Therefore, appropriate identi fi cation of individuals at high risk is important.
Several risk scores to predict type 2 diabetes have been developed. [4] [5] [6] [7] They vary in many ways, such as the time horizon for prediction and number and nature of predictors. Some models are based on non-laboratory clinical variables (non-invasive risk scores); others have also incorporated biological variables (invasive risk scores). Non-invasive risk scores have been shown to identify a high risk of type 2 diabetes (C statistics ≥0·8), although invasive risk scores are more successful (C statistics ~0·9). 8 The use of non-invasive risk scores is more likely to be cost eff ective and feasible for large-scale screening than is use of invasive risk scores. Generally, the use of risk scores has been widely incorporated into strategies for diabetes prevention. 9, 10 However, risk scores might not be generalisable from one population to another, and the validity of existing diabetes risk scores in diff erent settings and subgroups on the basis of sex or BMI has not been established. 10 We aimed to validate and compare existing noninvasive prediction models for type 2 diabetes in European populations. We assessed variability in predictive performance between countries and by sex, BMI, waist circumference, and age.
Methods

Study design and population
We used the EPIC-InterAct case-cohort sample (27 779 participants, of whom 12 403 had incident diabetes), which was selected from the European Investigation into Cancer and Nutrition (EPIC) cohort study (455 569 participants; appendix p 4). 11 The design and methods of the InterAct study have been described elsewhere. 11 Briefl y, the InterAct study was designed to investigate how genes and lifestyle factors interact to infl uence risk of type 2 diabetes. The InterAct consortium partners ascertained and verifi ed incident cases of type 2 diabetes in EPIC cohorts between 1991 and 2007, from eight of the ten EPIC countries (26 centres).
Participants gave written informed consent for participation in the EPIC study. The study was approved by the local ethics committees in the participating countries and the internal review board of the International Agency for Research on Cancer (Lyon, France).
Procedures
Self-administered questionnaires provided baseline information about lifestyle and medical history in the case-cohort sample. Validated instruments were used to assess nutritional variables 12 and physical activity. 13 Blood pressure and anthropometric measurements followed standard approaches (appendix p 5). We handled missing data in three ways: proxy variables (appendix p 6) or exclusion of the predictor from the model; exclusion of countries from specifi c analyses (appendix p 11); and imputation of missing values by country with R's AregImpute Function, which takes all aspects of uncertainty in the imputations into account by using the bootstrap to estimate the process of drawing predicted values from a full Bayesian predictive distribution. Existing non-invasive prediction models for incident diabetes had been identifi ed through a systematic review, as previously described. 8 We included in this study only models developed in general populations of European ancestry. We fi rst validated the original models by computing the predicted probability of diabetes for each participant in the EPIC-InterAct casecohort with baseline values (appendix p 7). We expressed models' performance in terms of discrimination (whether the model can distinguish between people who do and do not develop diabetes) and calibration (to what extent the predicted probabilities agree with the reported risk across groups of individuals). We assessed discrimination with the C statistic (which is comparable to the area under the receiver operator characteristic curve) adapted for time-to-event data.
14 C statistics vary from 0·5 (no discrimination) to 1 (perfect discrimination), with values of 0·7-0·8 deemed acceptable and 0·8-0·9 good. 15 We assessed calibration graphically with calibration plots, and by computing the ratio of expected to recorded probabilities and the accompanying 95% CIs by assuming a Poisson variance. 16 We also calculated the Yates slope (diff erence between mean predicted probability of type 2 diabetes for participants with and without incident diabetes, with higher values indicating better performance), and Brier score (squared diff erence between predicted probability and actual outcome for each participant; these values vary from 0 for a perfect prediction model to 0·25 for a noninformative model with 50% incident outcome). 17 We did not use tests of calibration such as the HosmerLemeshow test or U statistic, 18 because they are sensitive to study sample size.
Because we were comparing the performance of several models in a case-cohort design across many countries, we took some extra steps before model validation. First, the models have diff erent so-called time horizons. In the main analysis, we compared all models for prediction of type 2 diabetes within 10 years. Therefore, participants who developed diabetes after 10 years of follow-up were included as non-cases. Second, calibration is strongly aff ected by the outcome's incidence in the population; we therefore recalibrated models to the country-specifi c incidence through intercept adjustment (appendix pp 9, 12). 18, 19 These approaches eliminate diff erences between the models due to diff erences in incidence between the populations for which the scores were developed. 19 Third, the incidence of diabetes is artifi cially increased in the casecohort design. To arrive at the true incidences from the original cohort, we reconstituted the EPIC cohort within countries by applying a so-called blow-up approach to extrapolate the case-cohort data to a full cohort (appendix p 10). 8 Finally, to account for any heterogeneity between countries, we estimated the C statistic and ratio of expected to recorded probabilities for the entire cohort by pooling country-level estimates with random eff ects models. We then used the Cochran's Q and I² statistics to assess heterogeneity across countries.
We did the main analyses for each country and for subgroups defi ned by sex, age (<60 years vs ≥60 years), BMI (<25 kg/m² vs ≥25 kg/m²), and waist circumference (men <102 cm vs ≥102 cm; women <88 cm vs ≥88 cm). In four of the eight countries (Denmark, Italy, Spain, and Sweden), not all models had been validated (appendix p 11). We did a sensitivity analysis by restricting the assessment of the heterogeneity between countries to the four countries in which all models had been validated (France, Germany, the Netherlands, and the UK) to investigate if assessments of heterogeneity of diff erent models on the basis of a diff erent number of countries aff ected the comparisons. We also compared all models for prediction of diabetes within 5 years, which corresponds to the time horizon for predicted probability for six models.
We used the Hmisc, Design, Survival, and meta packages of R (version 2.13.0) for data analysis. 
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. APK and JWJB had full access to all the data in the study; JWJB, YTvdS, and NJW had fi nal responsibility for the decision to submit for publication.
Results
We validated 12 prediction models (table 1, appendix p 7). Age was a predictor of type 2 diabetes in all models except DESIR. 24 Most models were based on logistic regressions (table 1). Varying defi nitions for incident diabetes were applied (table 1). Data for baseline age and sex were available for all participants, but data were missing for some participants for some predictors (table 1) .
More than half the overall EPIC-InterAct study population were women, but the proportion varied by country (table 2) . French participants were all women, whereas the proportion of women among participants in other countries ranged from 44% to 81%. Mean baseline age was 54·1 years (SD 8·4) in men and 53·5 years (9·0) in women.
During the fi rst 10 years of follow-up, almost 10 000 cases of incident diabetes were recorded in the EPIC-InterAct population (table 2). Discrimination of the 12 prediction models was acceptable to good, with C statistics ranging from 0·76 to 0·81 (fi gure 1, table 3). For nine models, the recalibrated calibration curves mostly followed the ideal calibration line (fi gure 2; see appendix p 21 for calibration curves before recalibration). For the ARIC 2009 model, 21 the curves were mostly steeper than the ideal calibration line, with increasing risk (fi gure 2), indicating risk underestimation in highrisk participants. For the Cambridge 23 and DPoRT 25 models, calibration curves were fairly fl at, with increasing risk (fi gure 2), indicating risk overestimation in high-risk participants. Four models accurately estimated the overall rate of incident diabetes, six marginally overestimated or underestimated, and two largely overestimated (fi gure 2, table 3).
We noted signifi cant heterogeneity in discrimination across countries for all models except for the ARIC 2009 model (fi gure 1). The highest C statistics were almost always recorded in France, and the lowest mostly in Denmark (fi gure 1). The worst and best discriminating models varied by country (fi gure 1). Patterns of calibration were largely similar in each country to those recorded for the overall cohort (appendix pp 22-33). As expected, because of recalibration by country, we recorded almost no heterogeneity in calibration.
Discrimination was generally higher in women than men (table 3) . C statistics in men ranged from 0·73 to 0·79 in the overall cohort (table 3) , and from 0·68 to 0·86 across countries (appendix p 13). In men, the best discrimination was recorded in the Netherlands (appendix p 13). In women, C statistics ranged from 0·78 to 0·81 in the overall cohort (table 3) , and from 0·70 to 0·85 across countries (appendix p 13). The highest C statistics in women were mostly recorded in Germany, and the lowest in Denmark (appendix p 13). Calibration diff ered greatly between men and women per country, which could be masked by the overall ratio of expected to recorded probabilities (appendix p 13).
Discrimination was acceptable to good across age strata, and was always better in the younger age group than in the older (table 3) . Discrimination was below the acceptable range (C statistic <0·70) in the lower stratum of waist circumference but was acceptable in the upper one. Discrimination was similar across BMI groups, although C statistics were higher in people with increased BMI than in those with lower BMIs in seven of the 12 models (table 3) .
In terms of calibration, the ARIC 2005, 20 AUSDRISK, 22 FINDRISK concise, 6 and FINDRISK full models 6 acceptably predicted the overall rate of incident diabetes in age subgroups ( 27 and Potsdam 28 models. Absolute risk of diabetes was variably overestimated or underestimated by models across weight circumference strata, while all models systematically overestimated the risk within the lower BMI stratum (table 3) .
The pattern of overall event rate prediction in the four countries with valid data for all models (France, Germany, the Netherlands, and the UK) was very similar to that across all countries (data not shown), again with signifi cant heterogeneity for the Cambridge 23 and DPoRT 25 models (both p≤0·0002). Heterogeneity in discrimination across countries decreased when we examined data for countries with full data, with the ARIC 2009, 21 DPoRT, 25 and FINDRISK 6 models showing no heterogeneity (p>0·11).
During the fi rst 5 years of follow-up, 3698 cases of incident diabetes were recorded (table 2). Discrimination was slightly better and less heterogeneous at 5 years than at 10 years; otherwise, the pattern of predictions was broadly similar to that recorded at 10 years (appendix pp [16] [17] [18] [19] [20] [34] [35] [36] .
Discussion
We have shown that non-invasive models for prediction of incident type 2 diabetes have acceptable to good discrimination over 10 years, both overall and across countries. After recalibration, most models showed good calibration, which was consistent across countries, although discrimination varied signifi cantly. We showed that the models' performance is worse in men than in women. Discrimination is better in people younger than 60 years, but risk can be overestimated in this age group. Discrimination is generally lower in participants with a BMI of less than 25 kg/m² than in those with a BMI of at least 25 kg/m². Risk is systematically overestimated in participants with a BMI of less than 25 kg/m². No model signifi cantly outperforms others enough to be uniquely recommended for routine risk stratifi cation.
A few previous validation studies of incident diabetes models have been done. 4, 5, 8, 21, 24, [30] [31] [32] [33] [34] Most of those-mainly cross-sectional studies-compared several incident or prevalent risk scores in one population, 21, 24, [32] [33] [34] and another study compared three risk scores in a multiethnic population in the same country. 30 In one study, 8 the performance of both invasive and non-invasive prediction models for incident diabetes in a population was assessed. Overall, the previous studies showed that the models had modest to good discrimination and poor calibration. However, intercept adjustment to correct for diff erences in diabetes incidence between development and validation populations was done in only one study.
Models' performance (mostly discrimination) diff ered across countries in our study. This variation could be a result of diff erences in how predictors and outcomes 
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Ratios of expected to observed rates
We recorded substantial variation in models' performance by major subgroups, with consistently better performance in women than in men. For the DESIR 24 and DPoRT 25 models and the QDScore, 29 this diff erence could be a result of the use of sex-specifi c coeffi cients that could effi ciently capture the predictive information from risk factors. BMI and waist circumference are generally much stronger diabetes predictors in women than in men and could also explain these results. 37, 38 In our study, the diff erences in discrimination linked to BMI were small. BMI and waist circumference might not be linearly related to diabetes risk. 37 By including linear or categorical terms of these predictors, most models might not completely capture the nature of the associations. Our fi nding that discrimination is mostly better in younger than in older participants is consistent with a previous validation of the KORA model. 39 However, stratifi cation for a variable with discriminatory value by itself reduces discrimination.
The European guideline for the prevention of type 2 diabetes 10 and the International Diabetes Federation 9 recommend the use of reliable, straightforward, and practical prediction models to identify people at high risk of diabetes. Overall, our study shows that prediction models for type 2 diabetes are valid instruments for the identifi cation of individuals at high risk. However, this fi nding cannot directly be translated into a recommendation to use a specifi c model, because the decision to adopt a prediction model in any specifi c setting is driven by many factors, of which performance is only one. For individuals, highly accurate risk scores including biochemical testing are probably more relevant than non-invasive risk models are. 8 However, non-invasive risk scores could be used as part of the public health approach to diabetes prevention to identify individuals who should receive biochemical testing. Alternatively, a risk score could be used to identify a subgroup of the population for lifestyle intervention without additional testing. Mortality risk is increased in the large group of people who have positive risk scores, justifying direct action in this group. 40 Risk scores like those in the Cambridge model 23 and QDScore 29 in the UK, or the DPoRT model in Canada, 25 use data available from records in the countries where models were developed, and new data are not needed. Because such scores are likely to be applicable to anyone coming into contact with the health system, their performance could be better overall than that of another model with a slightly better discrimination. Nevertheless, a model for which a questionnaire is designed for self-screening at the population level (eg, the two FINDRISK models) might not be based on many responses, potentially overriding any performance advantage recorded in our analysis. 41 Therefore, the decision to use a particular model could be country specifi c and depends on factors other than model performance, such as availability of measurements in the setting where the model is used. Additionally, prediction of diabetes is useful only when used to implement interventions to aff ect the outcomes of high-risk people. 4 Diabetes prevention trials have been mostly based on a high-risk status defi ned by blood tests. However, implementation studies are necessary to investigate eff ectiveness of such risk scores. A few implementation studies have used risk scores to select participants for interventions and have shown favourable eff ects on risk factor levels 42 -eg, a moderate weight loss eff ectively reduced risk of type 2 diabetes after 1 year of intervention in participants selected with the FINDRISK score. 43 Our study has some limitations. Some of the approaches used to account for predictors that were completely missing (ie, proxy variables, predictor omission, and country's exclusion) could marginally decrease discrimination of the models. It is now widely accepted that deletion of participants with missing values (who are frequent in large studies) yields biased results. 39 Therefore, we applied robust methods to deal with missing data. 44 The large sample and the multicountry nature of our study has allowed us to assess and compare 12 models across countries for the fi rst time (panel). However, we did not include nonEuropean participants. Therefore, our results might not be generalisable to non-European countries or other ethnic groups. Finally, case defi nition was based on a clinical diagnosis of diabetes. Because diabetes can remain undetected, false-negative cases could have been present. Such false negatives could lead to an underestimation of the C statistic and aff ect the incidence of diabetes, aff ecting calibration of the risk scores. However, we adjusted for such eff ects of diabetes incidence by recalibrating the models.
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